
CDC scientists push back on vaccine presentations expected to cast doubt on immunization safety
Vaccines
Federal agencies
Respiratory viruses
Children's healthFacebookTweetLink
Follow
At the start of an unprecedented meeting of vaccine committee of the US Centers for Disease Control and Prevention, the agency scientists who normally generate and interpret data to inform this group's votes were in an unusual position: answering questions and countering statements that cast doubt on the safety and efficacy of approved vaccines.
In Wednesday's meeting, the agency experts answered polite but atypical queries about Covid-19 illnesses and vaccines, many focused on whether data could have been biased or misinterpreted, and whether patients counted as going to the hospital for Covid-19, might actually have had mild infections, but really been hospitalized for something else.
Thursday's agenda for the Advisory Committee on Immunization Practices includes two planned presentations on topics that have been fodder for vaccine skeptics for decades: one on a form of mercury used as a preservative in vaccines and another on the risks of rare febrile seizures after of some kinds of combination measles vaccines.
The presentations will be given not be given by CDC staffers or members of working groups that have met for months to discuss the topics, but by a newly appointed chair of the committee and a former leader of the anti-vaccine organization Children's Health Defense.
On Tuesday, CDC experts posted evidence reviews, labeled as background briefing material, on both topics online. By Wednesday, one of the documents – on the vaccine preservative thimerosal – had been taken down because it had not gone through the 'appropriate process to be posted,' a US Department of Health and Human Services spokesperson said.
Agency scientists often pull together available research in advance of these meetings to help brief ACIP members, and it's common for presentation slides to be posted ahead of time. But the posting of the CDC scientists' detailed briefing documents — and with no authors identified —was unusual, according to a former CDC official with knowledge of the group's processes.
Officials said it was a quiet sign of distress that career scientists are feeling as US Health and Human Services Secretary Robert F. Kennedy Jr. seeks to remake the process that informs vaccine recommendations.
'I find it very interesting that these documents were posted,' said the former CDC official, who asked not to be named for fear of retaliation.
It was clear from the questions asked by the new committee members on Wednesday that some are distrustful of evidence showing the safety and effectiveness of Covid-19 vaccines.
Following an announcement last month by HHS Secretary Robert F. Kennedy Jr. that Covid-19 vaccines were no longer going to be recommended for healthy children and pregnant women, the CDC showed data noting the continuing high rates of hospitalization for children younger than age 2.
The CDC noted that hospitalization rates for Covid-19 in babies and toddlers were roughly the same as for older adults last year.
Committee member Dr. Cody Meissner, a professor of pediatrics at Dartmouth University, pointed out that based on the CDC's latest data, roughly 1.6 of every 100,000 babies younger than 6 months were hospitalized for their infections during the week ending May 31.
'This is a very rare illness in young children as well as in adults now,' Meissner said.
Dr. Christopher Taylor, an expert on the CDC's respiratory disease data, responded that although the data on its website shows the current rates by week, the scientists used cumulative numbers over a year for their presentation.
In absolute terms, since July 2024, CDC data shows that 268 of every 100,000 babies under 6 months old were hospitalized for Covid-19; for adults ages 65 through 74, the same rate was 266 for every 100,000.
Children ages 6 to 23 months were hospitalized at rates on par with adults ages 50 to 64, about 100 for every 100,000.
'In cumulative numbers, this does remain a substantial burden for the youngest and oldest age groups,' Taylor said.
Healthy children can still receive Covid vaccines after consultation with a health care provider, a contingency known as shared clinical decision making. Though the recommendations for pregnant women has been dropped from the vaccine schedule, pregnancy remains a condition that puts people at higher risk of severe illness from the infection.
Meissner also asked whether Covid-19 hospitalizations reported by the CDC represented people who were severely ill from Covid-19 infections or whether those patients might be in the hospital for other reasons and happened to test positive for Covid-19 while they were there.
'People may have been hospitalized because of appendicitis, for example, and happen to have a positive [test] result, because we know that asymptomatic colonization is quite common with this virus,' he said.
But Taylor said that while it's true that the definition the researchers used depended on a lab-confirmed Covid-19 infection, their clinical data goes through another layer of scrutiny to see whether patients had symptoms consistent with Covid-19 or received medication consistent with a Covid infection.
Taylor added that early in the pandemic, many hospitals required all patients to be screened for Covid-19 during their stay — a practice that picked up infected people who initially came to the hospital for other reasons. Since then, however, most hospitals have dropped that practice.
Committee member Dr. Retsef Levi, a professor of operations management at Massachusetts Institute of Technology, asked about potential confounding in the CDC's studies, which he thought might be showing the opposite conclusions of what the scientists were presenting on efficacy of the current Covid-19 vaccines. He speculated that the control groups of the studies, which consisted of people who had other kinds of respiratory infections, were actually people damaged by Covid-19 vaccinations that put them at greater risk for those respiratory infections.
'In that case, you will assume that the vaccine is protective,' Levi said, 'but an alternative explanation would be that the vaccine is actually making you more vulnerable for multiple viruses.'
Dr. Ruth Link-Gelles, a CDC epidemiologist, said that control subjects were chosen to closely match the hospitalized patients with Covid-19 in terms of age and symptoms.
'We think that the controls here are exactly what we want to understand the relative impact of the vaccination,' she said.
Dr. Tracy Beth Hoeg, a senior adviser at the US Food and Drug Administration who participated in the meeting as liaison member, said she too had concerns about confounding in the CDC's studies and would have preferred to see data from randomized controlled trials.
'I think I share a lot of people on this panel's desire to see randomized control trials to minimize these types of bias so we aren't sitting here saying, 'Are we being misled by these data?' ' Hoeg said.
CDC experts say the study designs were chosen to generate timely results in a cost-effective way, to better understand the impact of vaccination on emergency department visits, hospitalizations and deaths in real time. CDC works with study sites to ensure that cases and controls are well-matched and minimize bias, they said.
'As for the question about clinical trials, I would actually defer that back to you all at FDA,' Link-Gelles said.
'Yeah, we're working on that,' Hoeg said.
Anti-vaccine groups have long blamed thimerosal for causing neurodevelopmental problems such as autism in children, despite numerous studies showing that it is not linked to those conditions.
Thursday's presentation on the topic will be given by Lyn Redwood, a nurse practitioner who was president of the World Mercury Project, a group that later 'expanded its mission' to become Children's Health Defense, which lists Kennedy as its founder and former chairman. Kennedy has described Redwood as one of the original 'mercury moms' who recruited him to join their fight against thimerosal in vaccines.
Redwood's presentation highlights data that she says shows that thimerosal is not effective at preventing bacterial growth in vaccines and isn't safe. She then proposes a recommendation that pregnant women, infants and children in the US get only thimerosal-free vaccines.
At least one of the studies referenced in Redwood's slides originally posted for the meeting didn't appear to exist. Those slides were later replaced with a version that didn't include the citation.
Before its removal, the CDC briefing document pointed out that since 2001, all childhood vaccines licensed and recommended in the US have been thimerosal-free, except some flu vaccines drawn from multidose vials, which are used infrequently. In the 2024-25 flu season, 96% of flu vaccines given in the US and 98% of flu vaccines given through the CDC's Vaccines for Children program were thimerosal-free, the CDC said in the document.
Dr. Peter Hotez, a pediatrician who directs the Center for Vaccine Development at Texas Children's Hospital, said that although Redwood's proposed recommendation may seem relatively toothless – most flu vaccines given to kids already are thimerosal-free – the basis for it is troubling.
'I'm worried that putting thimerosal on the agenda when it is no longer used in most pediatric vaccines serves no purpose other than to erode trust in our national vaccine and immunization programs,' Hotez said in an email to CNN. 'This has been a consistent pursuit by Mr. Kennedy and his associates.'
What's more, Hotez said, some low- and middle- income countries have to rely on multidose vaccine vials, and these formulations depend on the use of antibacterial preservative like thimerosal. If the US casts doubt on its safety, it could have ripple effects on vaccination programs around the world.
The CDC's evidence review said science shows that thimerosal doesn't harm children's brains.
'Considering the breadth of evidence and consistency in results from multiple population-based studies conducted in several countries with various study designs, the evidence does not support an association between thimerosal-containing vaccines and autism spectrum disorder or other neurodevelopmental disorders,' the briefing document said.
Another presentation on the agenda, to be made by Dr. Martin Kulldorff, on the combination MMRV vaccine in kids under 5, had not been posted to the ACIP website as of Wednesday night.
The CDC briefing document explains that since 2009, ACIP's vaccine schedule has recommended giving the measles, mumps and rubella (MMR) vaccine and the varicella vaccine separately in children who are 1 to 2 years old.
Giving the shots separately cuts a very small additional risk of fevers with seizures that can happen when all the vaccine components are combined. The added risk amounts to 1 case of febrile seizure for every 2,300 to 2,600 vaccinated kids. Giving the vaccines separately avoids it.
The review notes that even when these seizures happen, they resolve without long-term consequences.
'Although rare cases of encephalitis and death have been reported after MMRV vaccination, no direct link between these events and the vaccine has been established in persons with healthy immune systems,' the review said.
Kulldorff announced Wednesday that a new CDC work group will look at vaccines for measles, mumps, rubella and chickenpox, or varicella. It may reevaluate the combination vaccine recommendation for 1-year-olds, the optimal timing of the vaccine and potential alternatives, such as one used in Japan.
CNN's Meg Tirrell contributed to this report.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Stung by high prices, Americans make their own weight-loss drugs
By Robin Respaut and Maggie Fick SAN FRANCISCO (Reuters) -In what she calls the "wild west" of obesity medicines, Missouri-based Amy Spencer is a pioneer. Each week the mother of two injects herself with weight-loss drugs, two of which are in clinical trials and not yet approved for sale by the U.S. Food and Drug Administration. One comes mixed with tirzepatide, the active ingredient in Eli Lilly's Zepbound. Spencer, 50, is not part of any drug trial but mixes the cocktails herself, using tiny doses that she believes are safe. The total cost is about $50 monthly, as little as one-tenth of what she would expect to pay their makers for full treatment. The drugs – glucagon-like peptide-1 (GLP-1) weight-loss medicines – are manufactured and shipped from China, according to the packaging. She orders them through online vendors. Spencer belongs to a fast-growing group of Americans turning to what many call the "gray market" for obesity medicines, bringing cheap active ingredients from China often labeled as for research purposes, according to import data and social media postings. It's a trend that drugmakers Lilly and Novo Nordisk, which makes Wegovy, say is dangerous as well as illicit. Reuters tracked online forums and interviewed seven people who said they bought obesity medicines through this market, including an attorney in Arizona who works for a state insurance agency, a retired nurse in Illinois and a Type 1 diabetic in Louisiana, who said the medicine helped cut her insulin intake by more than half. For more than a year there has been demand for cheap Chinese-made powders, exacerbated by limited health insurance coverage in the U.S. Buyers told Reuters the gray market received a boost from an FDA ruling last year that U.S. compounding pharmacies – outsourcing facilities that create drugs in shortage – must stop selling obesity medicines more cheaply than the companies that developed them. Shipments of such active ingredients from Chinese entities not registered with the FDA jumped by 44% in January from the previous month, according to research by the Partnership for Safe Medicines, a public health group focused on the safety of prescription drugs. It said its findings are likely an undercount, because unregistered vendors may not disclose that their parcels contain medicines. Packages valued at less than $800 that enter the U.S. under the de minimis rule are not included in the data. Nearly three-quarters of U.S. adults are overweight or obese, according to government estimates, but a survey by nonprofit health policy research organization KFF found only about 8% say they have taken medicine for weight loss. Most of the gray market buyers Reuters interviewed had told their medical providers they were taking GLP-1 medicines but not where or how they bought them. Insurance coverage for weight-loss drugs has recently increased, but typically only covers branded versions, according to consulting firm Mercer. Many Americans have paid out of pocket for cheaper compounded drugs. Interest in taking small doses of the drugs has also spurred the online marketplace, buyers said. Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research materials to sidestep regulatory scrutiny. They swap advice for navigating the market, exchanging information on vendors, shipping and dosage, and sometimes clubbing together to cover the cost of testing the powders. One forum is called StairwayToGray. It has more than 21,000 members on Telegram and recently was gaining nearly 1,000 members weekly. It did not respond to Reuters' inquiries, and blocked access to the forum after receiving them. It has a website where it says it does not facilitate group purchases. "This community is filling the gaps and being our own regulators, ensuring testing and access for everyone who needs it. Because you shouldn't have to choose between your health or your wallet," it says. Spencer stores her stocks in her fridge and makes them up in the kitchen – carefully measuring sterile water, rolling the vial between her fingers until the powder dissolves, and drawing the liquid into a syringe before injecting it into her thigh or belly. She has lost 24 pounds. "This is working so well for me. It's so easy. It's cheap," said Spencer, who assumes her health plan wouldn't cover the drugs. "I don't know what I would do without this medicine." "VERY DANGEROUS" In February, 38 U.S. state and territory attorney generals wrote the FDA seeking action against illegally sold weight-loss medicines, including "research purposes only" ingredients from China. "Much like with counterfeit versions, these active ingredients come from unregulated, undisclosed sources ... and pose risks of contamination and inclusion of foreign substances," they said. Shabbir Safdar, executive director of the Partnership for Safe Medicines, said unapproved drugs can have problems with sterility, purity and consistency. "It can be very dangerous. You're playing the role of your own doctor, pharmacist, and FDA inspector," he said. Of those interviewed, only Spencer reported any problems: She once got her math wrong and overdosed, resulting in several days of severe flu-like symptoms. Lilly said it had taken many steps to address patient safety risks posed by the proliferation of unsafe or untested tirzepatide. The company said it is filing lawsuits, educating consumers and working with social media companies to identify and remove posts that promote unsafe products, including those described as "research use only." "We will continue to take action to stop those who threaten patient safety and urgently call on regulators and law enforcement to do the same," a Lilly spokesperson told Reuters. Novo Nordisk also said it continues to take action against entities that violate laws and regulations and put patient safety at risk. America's Poison Control agency, which maintains the nation's poison data surveillance system and monitors GLP-1 exposures, said it could not reliably track cases involving unregulated "research chemical powders" because they are sold under various names and formulations. The FDA's goal is to stop illegal sales of pharmaceutical medicines at the border, said George Karavetsos, former director of the FDA's Office of Criminal Investigations and co-author of the imports study. But understanding the true nature and intended use of small parcels arriving from China can be difficult, and the FDA rarely seeks charges against consumers for personal use, he said. The FDA said it urges consumers to buy from licensed pharmacies and "avoid products of unknown quality," adding it was actively protecting consumers by intercepting illegal products at ports, and warning companies that market unapproved weight-loss medicines, including those mislabeled as "for research purposes." Although the forums show suppliers purportedly in China, Reuters was not able to verify where the drugs originate. None of the vendors responded to requests for comment. A Reddit spokesperson said the site prohibits facilitating transactions involving drugs and it had shut down a group found to be doing this. Telegram said it removes "more than a million" instances of harmful content each day, but did not comment directly. MICRODOSE MISTAKE Spencer has polycystic ovary syndrome and for years struggled with weight gain and hypertension. She decided to try obesity medicines after seeing claims on social media that microdosing them could give fewer side effects, and bought semaglutide, the active ingredient in Wegovy, from a compounding pharmacy for about $200 per month. She started on one-fifth of the lowest dose. Within days, intermittent joint pain she often suffered had dissipated: "I didn't realize how badly I hurt until the pain was gone." The cost would reach about $500 a month if she bought the drug from Novo, which recently introduced one-off discounts. After a week, Spencer said, her blood pressure dropped so low she thought she might pass out, so she stopped taking hypertension medicine. Her pressure stabilized and she lost three pounds. She wanted to understand more about microdosing, and turned to the gray market last summer. On Reddit, users told how another Novo drug in development, called CagriSema, had helped reduce inflammation and hunger pangs better than semaglutide. CagriSema is Novo's next-generation obesity drug candidate, still in clinical trials so not available to the public. It combines semaglutide with another molecule, called cagrilintide, which intensifies the hormone-mimicking effects to regulate blood sugar and reduce hunger. Spencer was intrigued. She found a U.S. reseller saying they tested Chinese-made CagriSema through a third-party lab before selling it to Americans. On microdoses of CagriSema, Spencer could enjoy food in small quantities. "I could say 'yes' because I knew I was only going to eat four bites." In October, Spencer saw on Reddit that tirzepatide might also reduce inflammation. She placed a new order for vials that contained cagrilintide and tirzepatide combined, dubbed "cagri-tirz." Now each Monday, Spencer injects herself with tiny amounts of cagri-tirz. On Thursdays, she uses retatrutide, a new obesity medicine by Lilly, also in trials. As she was switching to cagri-tirz, Spencer made a dangerous mistake. She calculated her new dosage without realizing the concentration of cagrilintide in the combined vials was 10 times higher than she had taken previously. "I was an idiot. I didn't do my math. Or rather, I did the math for the tirzepatide but not for the cagri," she said. Almost immediately, she began vomiting. The reaction was so severe she had trouble moving. She forced herself to drink water but couldn't eat. After four days, when symptoms lifted, she had lost seven pounds. Despite the blunder, Spencer didn't consider returning to compounded versions of the drugs or abandoning them altogether. She is not regularly monitored by a healthcare provider, but says her treatment has led to a "life-changing" reduction in weight, joint pain and blood pressure. "HONOR SYSTEM" Gray-market buyer Marie, 41, shows how do-it-yourself drugmakers are organizing. She describes herself as a "soccer mom" from the Midwest and asked to be identified by her middle name to protect her privacy. Last year she bought a compounding pharmacy's version of tirzepatide, paying about $470 monthly, and had lost more than 20 pounds when the FDA announced the ban on compounded weight-loss drugs. She began to worry about her supply. Browsing on Reddit, she discovered links to Telegram and a trove of detailed instructions from experienced users for buying weight-loss drug ingredients from China. Customers said they often paid with Bitcoin or through mobile payment service Venmo. After a month closely following the forums, Marie made a purchase in January. The package that arrived contained 20 small glass vials of white powder with red caps. There were no instructions. The vendor who advertised the package on Telegram said it came from China. Marie returned to the forums and joined a group of 52 other customers who paid a total of $1,020 to a Tennessee-based company called Peptide Test. Six members mailed in a vial each and the others chipped in their share of the fee. The lab found the samples were pure. Peptide Test declined to comment. "It's an honor system," said Marie. "These groups are very supportive in a way I haven't seen on the internet before." Before her first injection, Marie gave her husband details of what she had done. They agreed that if needed, he would disclose everything to the emergency medics. But she was fine. In March, Marie volunteered to organize testing a new order of tirzepatide. The group formed on Telegram after users received vials from the same vendor which they judged to be from the same batch based on the color of the caps. In all, 38 buyers agreed to chip in for the $1,300 bill, and decided by poll that five vials would be enough. Five people sent drugs to the lab, Janoshik Analytical in the Czech Republic, which found the vials contained tirzepatide, as purported, with purity between 99.78% and 99.85%. Janoshik's CEO, Peter Magic, is a former amateur weight-lifter. He said his company started out more than a decade ago testing performance-enhancing drugs for online buyers. Last year, it tested 3,050 samples of obesity drugs, up from just over 650 samples in 2023. "We're testing hundreds of these every week," said Magic, whose company helps customers navigate customs requirements for shipping chemicals.

Vogue
33 minutes ago
- Vogue
Why a Tinted Sunscreen Might Actually Be Better Than Your Average SPF
Mineral versus chemical, cream versus oil, ideal SPF filter—there are many factors to consider when shopping for the best sunscreen. But of all the questions posed, the latest discourse has been around tinted versus un-tinted, which is better? Vogue's Favorite Tinted Sunscreens 'I wouldn't say that tinted sunscreens are overall better than traditional sunscreens (as a dermatologist, getting patients to regularly apply any sunscreen is a win!), but I will say that tinted sunscreens are better for certain skin needs than other kinds of sunscreens,' board-certified dermatologist Dr. Corey L. Hartman tells Vogue, and fellow dermatologist Dr. Elyse Love agrees. 'Tinted sunscreens are similar to their un-tinted counterparts from an SPF filter perspective, but they contain added pigment in the formula—typically composed of iron oxide and pigmentary titanium dioxide,' which she says provides visible light protection. 'This is particularly relevant for darker skin tones. Visible light can cause and worsen pigmentation in darker skin tones.' Basically, as nurse practitioner Catie Boucher explains, the iron oxides that give the tint, act as a physical barrier on the skin to reflect and scatter visible light. 'More specifically, iron oxides also shield against another component of visible light called blue light,' she says. 'We know that blue light can stimulate pigment cells known as melanocytes, which can lead to pigmentation disorders such as melasma. When it comes to treating and preventing pigment disorders, it takes a village. Choosing a tinted sunscreen provides another layer of protection that is much needed.' So, anyone with deeper skin tones or pigmentation prone (be it melasma, post-acne scarring, or sun spots, should consider working in a tinted sunscreen instead. And there's a wealth of evidence to support it, too. Hartman cites a 2022 research study, for example, that demonstrates using tinted sunscreen as an effective strategy in reducing melasma. Naturally, narrow, 'universal' shade ranges pose a challenge to finding an appropriate tint; a limitation and an outdated norm the industry is finally moving away from. In recent years, thoughtful reformulations of the best tinted sunscreens have coincided with more expansive offerings, taking into account varied undertones and shades from fair to deep. Merit's latest, The Uniform, features 15 shades, mirroring those of its beloved The Minimalist complexion stick. It's a similar story across the pond for Beauty of Joseon's tinted serum, offering 12 shades in an impressive range. Even La Roche-Posay recently introduced three new shades to its classic Anthelios Tinted Sunscreen SPF 40+—now offering Medium, Medium Deep, and Deep alongside a separate universal tint. And for those more interested in a glow, options by iNNBeauty Project and Kosas work to illuminate and bronze the complexion, adding a radiant gleam in lieu of a traditional complexion-evening tint.


New York Times
38 minutes ago
- New York Times
An MLB manager found value in long walks. Research suggests it's a ‘brain-changing power'
For most of his adult life, Bruce Bochy has been a walker. Long strolls, short saunters, usually along water. When he managed the San Francisco Giants to three World Series championships, he often wandered the city's steep hills with his wife, Kim. On the road, he kept a daily routine: An afternoon walk to the ballpark, no music, no podcasts, just his thoughts. Advertisement 'Sometimes we get caught up in the game,' Bochy said. 'We let that define us. That's a very important part of our life, but I don't want that just to be my sense of significance. It's family and health. So that's part of my way of trying to stay healthy. Not just physically, but on the mental side.' Bochy, 70, isn't as nimble as he once was. He possesses two new hips and an artificial knee. In his third year with the Texas Rangers, he walks slowly, a hitch in his deliberate gait. But he still believes in the power of a good walk — an hour of exercise, fresh air and contemplation, a peaceful break to mull lineup decisions, brainstorm tactics and ideas and think through tough conversations with his players. 'I felt like I did something,' Bochy said. When it comes to walking, Bochy is one of sports' biggest enthusiasts; he even wrote a whole book about walks. But he's hardly alone. Former Apple CEO Steve Jobs was famed for his walking meetings. Ernest Hemingway was said to walk around the Seine in Paris to solve writer's block. And the famed psychologists Daniel Kahneman and Amos Tversky sharpened their biggest ideas while on long, meandering walks. 'I did the best thinking of my life on leisurely walks with Amos,' Kahneman wrote in the 2011 book, 'Thinking, Fast and Slow.' In a world of Fitbits, iPhone health apps and other tracking devices, it might seem that walking's benefits are properly appreciated and understood. But Shane O'Mara, an Irish neuroscientist and writer, maintains that walking is a 'brain-changing power' which remains overlooked. At the very least, O'Mara is something of a walking evangelist. Whether you're an MLB manager, an executive, an elite athlete or anyone else, it can meaningfully improve your life. And if walking leads to more creativity and clearer thoughts, O'Mara pushes forward the following idea: Maybe it's something we should all be thinking about more. Bochy's walking habit has a familiar origin story. It started when his family got a dog, a black lab named Jessie. Bochy was managing the San Diego Padres and the task of walking the dog fell to him. Soon enough, he came to love the walks around nearby Poway, Calif., as much as he loved the dog. (And he really loved the dog.) Advertisement When Bochy joined the Giants in 2007, the ritualistic walks came with him. The benefits were consistent. One summer night in Milwaukee, after a brutal collapse against the Brewers, Bochy found himself sitting alone in his office, ruminating over the loss. Finally, he thought: I'm gonna walk home. It was maybe four miles, and it was late, and the Brewers' stadium is not exactly pedestrian-friendly. But when Bochy reached the team hotel, he felt better. Bochy kept up the routine as the Giants made World Series runs in 2010 and 2012, exploring cities and taking in San Francisco's neighborhoods. As it happened, those championship seasons came just as another Bay Area resident started thinking deeply about the value of walking. Marily Oppezzo was a dietitian and health researcher at Stanford in nearby Palo Alto, working on her PhD in educational psychology. Her doctoral adviser, Daniel Schwartz, was a believer in the 'walking meeting,' opting for discussions during strolls around campus. Oppezzo was interested in finding ways to integrate more exercise into the workplace. One day, during a conversation about her dissertation topic, Oppezzo asked Schwartz a question: 'Why do we do walking meetings?' Schwartz said they helped him think through new ideas. Oppezzo thought for a moment. Had anyone ever tested that? The question planted the seed for the first set of studies to measure if walking produces more creativity. In a series of experiments, Oppezzo and Schwartz asked 176 college students to complete different creative-thinking tasks while sitting, walking on a treadmill, walking outside through campus or being pushed in a wheelchair. In one example, the students had to come up with atypical uses for random objects, like a tire or a brick, a common marker of creativity. On average, the students' creative output increased by 60 percent when they were walking. Advertisement What made the results even more interesting was that it wasn't just about the environment surrounding the students. For years, writers and thinkers had theorized that the benefits of a walk stemmed from the stimuli we experience in nature — the changing views, the fresh air, the green space. But Oppezzo found something different. Yes, people saw an increase in creativity when being pushed through campus in a wheelchair. But people saw an even bigger increase when walking indoors on a treadmill. 'Walking beat it,' Oppezzo said. 'There was something about pushing through the space.' There were limits, though. While walking was ideal for divergent thinking — idea generation, daydreaming, making narrative connections — it was mostly useless when it came to convergent thinking, or the kind of focused thinking one needs for quick math in your head. It was an idea that Kahneman described in 'Thinking, Fast and Slow.' The next time you're on a walk with a friend, he wrote, ask them to do 23 x 78 in their head. They will almost surely stop walking. Oppezzo found the same in one unpublished study. The participants could not do quick math. 'People were just garbage at it,' she said. When Oppezzo and Schwartz's research was originally published in the Journal of Experimental Psychology: Learning, Memory and Cognition in 2014, it inspired a short cycle of media attention. Oppezzo eventually gave a TED Talk. But there was also a second response. 'Everyone was like: 'Oh, we already knew this,' ' Oppezzo said. Scientists, though, were still trying to understand why. One day earlier this year, not long after speaking to Bochy, I went for a morning walk. The conversation with Bochy had sparked an idea for a story, but as I walked and listened to music, sipping from a cup of coffee, my mind began to wander, and a familiar process took root. A series of ideas began to collide, and a mental mapping process began, constructing the scaffolding for a basic story structure in my head. Advertisement As a writer, it's hard to describe how or why this happens. One of my friends, a fellow writer and walking enthusiast, once told me he thought of this experience as 'inactive work.' O'Mara, the Irish neuroscientist, says that 'walking is, paradoxically, a form of active idleness.' You are not focused on unlocking an idea; it just happens. Neuroscientists describe being in this mind-wandering state as part of the default mode network, one of the brain's primary networks. It's active when we reflect on our pasts or imagine our futures. It helps us conceive narrative and make sense of the world. A second major network is the executive control network, which is active when we are using more focused thinking and problem solving. We use this network when we are solving a math problem or searching for one correct answer. 'The ability to think creatively seems to be the combination of these two systems working together,' said Roger Beaty, the director of the Cognitive Neuroscience of Creativity Lab at Penn State University. 'So it's not just super spontaneous, random thinking, or all focused, logical thinking. But the synchrony of those two systems.' According to O'Mara, there are reasons that walking enables this toggling between mental states. Mild exercise can increase blood flow, boost our mood and enhance alertness. And bodily movement itself drives activity all over the brain. 'This activity allows ideas just below the level of consciousness to come into consciousness,' O'Mara said. But in most cases, walking is not the kind of exercise that can spike our heart rate. Nor are we overwhelmed by stimuli. There is a reason, after all, that we rarely daydream while sprinting or amid an intense basketball game. It's also why our minds don't wander as much if we walk while listening to a podcast or an audiobook. Advertisement O'Mara described the dynamic in his 2019 book, 'In Praise of Walking: A New Scientific Exploration.' The part of the brain that is active when we are walking, jogging or moving is the extended hippocampal formation, which is also the section that is active when we access memories. 'Mind-wandering allows the collision of ideas, while mind-focusing allows you to test whether it is nonsensical or interesting and new,' O'Mara wrote. 'The more we look, the more we find that the hippocampus plays a central role in both these activities.' Put another way: There are other possible inputs — or ways — to generate ideas. But walking acts as a useful catalyst. 'It is a simple hack,' O'Mara said. Scientists have continued to examine the relationship. In 2023, a creativity researcher at the University of Graz in Austria led a study that reinforced the findings from Stanford. Using sensors to track movement and mobile phone prompts to test a group of college students, the group was able to take research out of the lab and into a real-world environment. The group found that, on average, people who were more physically active had more creative ideas. In addition, a person's number of steps five minutes before doing a creative task was associated with an increase in the originality of their verbal ideas. 'If a person was walking more,' said Christian Rominger, the creativity researcher and lead author on the study, 'they were more creative.' In his prime, Bochy usually cruised past 10,000 steps per day. The number has become a benchmark for millions around the world. The origins were more marketing than science. The target dates back to the 1960s in Japan, according to I-Min Lee, a professor of epidemiology at Harvard who has researched step counts. After Tokyo hosted the Olympics in 1964, a company in Japan produced a pedometer device called a Manpo-kei, which translates to '10,000 steps meter.' Advertisement It was a nice round number — roughly equal to 5 miles — but research has shown that a better target may be 7,500 steps. O'Mara offers another guideline: 5,000 more steps than you're doing now. As the 19th-century Danish philosopher Søren Kierkegaard once said, 'Every day, I walk myself into a state of well-being and walk away from every illness.' For those who do it daily, walking is more than exercise. It is a time machine to the past, a window to our possible futures, a tool to sharpen our thoughts and ideas, our hopes and desires. For Bochy, it has always been a time to decompress. When he managed the Giants, he lived in a condo not far from the ballpark. His walk to work was short, less than 10 minutes. After games, win or lose, he would head into the night and walk home. (Illustration: Dan Goldfarb / The Athletic; Mitchell Layton, Brace Hemmelgarn/Minnesota Twins / Getty Images)